Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04110743
Other study ID # 1341792
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 19, 2019
Est. completion date December 19, 2023

Study information

Verified date August 2023
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this pilot study is to collect preliminary data using total body scans on a new, first of its kind, FDA 510k-cleared positron emission tomography/computed tomography (PET/CT) scanner, called EXPLORER.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 45
Est. completion date December 19, 2023
Est. primary completion date December 19, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women, 18 years of age or older - Willing and able to fast for at least 6 hours before and for the duration of the scan - Willing and able to lay motionless in a supine position for 60 and 20 minutes at separate timepoints. - Willing and able to give informed consent Exclusion Criteria: - No Primary Care Physician - Body weight >240 kg - Allergy to iodine contrast (only for subjects enrolled in Arm 3) - Creatinine levels > 1.5 mg/dL or estimated glomerular filtration rate (eGFR) < 60 ml/minute (only for subjects enrolled in Arm 3) - Recent (1 month) contrast enhanced CT - Any known concomitant acute infection (including upper respiratory infection, genitourinary infections, etc. - History of metastatic or newly (last 5 years) diagnosed locally invasive cancer. - Chemotherapy in the last 5 years - Radiation therapy in the last 3 years - Major surgery within the last 6 months. - Pregnancy or breast-feeding - Diabetes - Fasting blood glucose level > 160 mg/dL before administration of FDG - Prisoners - The standard MRI contraindications apply, including but not limited to: Having a pacemaker or other implanted electronic device. Metal foreign bodies, aneurysm clips, heart valve prosthesis, vascular stents, cochlear implants, embolization coils, gunshot wounds with retained bullet fragments, penile implant, IUCD. Claustrophobia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EXPLORER PET/CT
Intervention: PET/CT using different protocols

Locations

Country Name City State
United States University of California, Davis Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Davis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Standardized Uptake Value SUV(t)= C(t)/ID/BW C(t) is radioactivity measured at the time t, decay corrected to t=0 and converted from a volume to a mass based unit via the factor 1/(1 g/mL) ID: the injected dose at t=0 BW= Body weight To collect preliminary data regarding FDG biodistribution as a function of time. Time-activity curves will be created approximatively 12 hours
Primary Coefficient of variation. SD/mean (Standard deviation divided by mean value) To obtain preliminary data regarding low dose EXPLORER noise level approximatively 3 hours
Primary Standardized Uptake Value To collect preliminary data about total body FDG perfusion and early biodistribution. Time-activity curves will be created approximatively 1 hour
Primary Standardized Uptake Value SUV(t)= C(t)/(ID/BW) C(t) is radioactivity measured from an image at the time t, decay corrected to t=0 and converted from a volume to a mass based unit via the factor 1/(1 g/mL) ID: the injected dose at t=0 BW= Body weight To obtain preliminary data to understand whether intravenous iodinated contrast agent produce a significant change in quantification of FDG uptake levels.
Time/activity curves will be generated.
approximatively 2 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1